1. Pink Sheet
  2. >>Geography
  3. >>Europe

Joined-Up EU Approach Is Key To Continuing COVID-19 Fight

Multi-Stakeholder Approach Must Be Maintained, Medicines For Europe Insists

 
• By Dave Wallace

At a Medicines for Europe webinar on learning lessons from the COVID-19 pandemic, a clear consensus emerged that a continued co-ordination between industry, regulators and the European Commission was key to both effectively address the current crisis and ensure a greater level of preparedness for similar challenges in future.

Europe
A continued co-ordinated approach to tackling the coronavirus is important • Source: Shutterstock

Continued high-level co-ordination between the off-patent industry, regulators and the European Commission is key to ensure that the region continues to effectively address the coronavirus pandemic, as well as preparing itself for future similar crises, according to participants at a roundtable hosted by off-patent industry association Medicines for Europe.

Speaking today as part of a panel at a webinar on “lessons learned from COVID-19,” Teva’s Christoph Stoller, president of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

UK’s Decentralized Manufacturing Rules Designed To Allow For ‘Future Developments’

 
• By Eliza Slawther

The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges

US FDA’s Top Cell and Gene Therapy Regulators Forced Out

 
• By Sarah Karlin-Smith

Office of Therapeutic Products Director Nicole Verdun and her deputy Rachael Anatol were escorted out of FDA headquarters on June 18. Disagreements over CAR-T regulation and Capricor’s DMD treatment may be to blame.